voretigene neparvovec-rzyl for leber congenital amaurosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Aug 2007: Trial registered, NCT00516477
  2. 20 Mar 2018: Trial completed, NCT00516477

The trials

NCT00516477: Safety Study in Subjects With Leber Congenital Amaurosis

State
Completed
Phase
Phase 1
People
12 planned
Started
Sep 2007
Primary completion
20 Mar 2018
Arms
dose cohort 1, dose cohort 2, dose cohort 3
Results
None posted
  1. 15 Aug 2007: Trial registered
  2. 20 Mar 2018: Trial completed

NCT01208389: Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2

State
Under way
Phase
Phase 1 and Phase 2
People
12 planned
Started
Nov 2010
Primary completion
Oct 2027
Arms
voretigene neparvovec-rzyl (AAV2-hRPE65v2)
Results
None posted
  1. 24 Sep 2010: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.